Alferon LDO

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HIV Infections

Conditions

HIV Infections

Trial Timeline

Jul 1, 2005 → Apr 1, 2009

NCT ID

NCT00215852

About Alferon LDO

Alferon LDO is a phase 2 stage product being developed by AIM ImmunoTech for HIV Infections. The current trial status is terminated. This product is registered under clinical trial identifier NCT00215852. Target conditions include HIV Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00215852	Phase 2	Terminated	Jul 1, 2005	Apr 1, 2009	HIV Infections
NCT00215826	Phase 2	Completed	Nov 1, 2004	Apr 1, 2006	Severe Acute Respiratory Syndrome

Competing Products

20 competing products in HIV Infections

See all competitors

Product	Company	Stage	Hype Score
AAVLP-HPV + Placebo	2A Pharma	Phase 1	25
VN-0200 + Placebo	Daiichi Sankyo	Phase 1	33
VN-0200	Daiichi Sankyo	Phase 2	52
Micafungin	Astellas Pharma	Pre-clinical	23
amphotericin B liposomal (Ambisome)	Astellas Pharma	Approved	85
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	23
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus	Astellas Pharma	Approved	85
Micafungin	Astellas Pharma	Pre-clinical	23
Micafungin	Astellas Pharma	Phase 1	33
Micafungin + Placebo	Astellas Pharma	Phase 3	77
Cefiderocol + Standard of Care	Shionogi	Phase 2	52
Dolutegravir + Rlipivirine + GSK1265744	Shionogi	Phase 1	33
Xeruborbactam Oral Prodrug + Ceftibuten	Shionogi	Phase 1	33
Cefiderocol + Standard of Care	Shionogi	Phase 2	52
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice daily	Shionogi	Phase 3	77
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten Placebo	Shionogi	Phase 1	33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granules	Shionogi	Phase 1	33
GW810781	Shionogi	Phase 2	52
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusion	Shionogi	Phase 1	33
Cefiderocol	Shionogi	Phase 2	52

Other Products from AIM ImmunoTech

AmpligenPhase 3

Alferon LDOPhase 2

poly I-poly C12UPhase 2

EC Aspirin + Recombinant Interferon Alfa-2b + RintatolimodPhase 2

poly I-poly C12UPhase 2